Skip to content

Clinical trials

Completed Phase 1 Acquired Immunodeficiency Syndrome trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Acquired Immunodeficiency Syndrome Phase: Phase 1 Status: Completed Clear all

387 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20031
20041
20054
20064
20073
200811
200915
201017
201115
201211
20138
201419
201521
201617
201716
201811
201912
20209
20217
202211
20237
20241
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed387

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Institute of Allergy and Infectious Diseases (NIAID)108
ViiV Healthcare74
GlaxoSmithKline14
Merck Sharp & Dohme LLC9
Rockefeller University8
Gilead Sciences6
Tibotec Pharmaceuticals, Ireland5
Bristol-Myers Squibb4
Daiichi Pharmaceuticals4
International AIDS Vaccine Initiative4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Acquired Immunodeficiency Syndrome387
HIV Infections215
AIDS-Related Complex87
Infections75
Sarcoma, Kaposi18
AIDS-Related Opportunistic Infections16
Cytomegalovirus Infections9
Multiple Acyl Coenzyme A Dehydrogenase Deficiency9
Cytomegalovirus Retinitis7
Pneumonia, Pneumocystis7

Trials

Showing 1 to 25 of 387. Each trial links to its page on Pharma Observatory.

287 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.